No Association between TGFB1 Polymorphisms and Late Radiotherapy Toxicity: A Meta-Analysis

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Zhu, Mei Ling ^a   Wang, MengYun ^b   Shi, Ting Yan ^b   Li, Qiao Xin ^b   Xi, Pan ^a   Xia, Kai Qin ^b   Zheng, Leizhen ^a   Wei, Qing Yi ^b,c,d  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CANCER CLASSIFICATION; ETHNICITY; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; MOLECULAR PATHOLOGY; RADIATION INJURY; RISK ASSESSMENT; SAMPLE SIZE; SINGLE NUCLEOTIDE POLYMORPHISM; TGFB1 GENE;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; RADIATION INJURIES; RADIOTHERAPY; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84885125646     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076964     Document Type: Article

References (41)

1. Bentzen SM, (2006) Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer 6: 702-713. doi:10.1038/nrc1950. PubMed: 16929324.
2. West CM, (1995) Invited review: intrinsic radiosensitivity as a predictor of patient response to radiotherapy. Br J Radiol 68: 827-837. doi:10.1259/0007-1285-68-812-827. PubMed: 7551778.
3. Andreassen CN, (2010) Searching for genetic determinants of normal tissue radiosensitivity--are we on the right track? Radiother Oncol 97: 1-8. doi:10.1016/j.radonc.2010.07.018. PubMed: 20817285.
4. Alsner J, Andreassen CN, Overgaard J, (2008) Genetic markers for prediction of normal tissue toxicity after radiotherapy. Semin Radiat Oncol 18: 126-135. doi:10.1016/j.semradonc.2007.10.004. PubMed: 18314067.
5. Martin M, Lefaix J, Delanian S, (2000) TGF-beta1 and radiation fibrosis: a master switch and a specific therapeutic target? Int J Radiat Oncol Biol Phys 47: 277-290. doi:10.1016/S0360-3016(00)00435-1. PubMed: 10802350.
6. Anscher MS, (2010) Targeting the TGF-beta1 pathway to prevent normal tissue injury after cancer therapy. Oncologist 15: 350-359. doi:10.1634/theoncologist.2009-S101. PubMed: 20413640.
7. Barnett GC, Elliott RM, Alsner J, Andreassen CN, Abdelhay O, et al. (2012) Individual patient data meta-analysis shows no association between the SNP rs1800469 in TGFB and late radiotherapy toxicity. Radiother Oncol 105: 289-295. doi:10.1016/j.radonc.2012.10.017. PubMed: 23199655.
8. Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, et al. (1999) Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet 8: 93-97. doi:10.1093/hmg/8.1.93. PubMed: 9887336.
9. Dunning AM, Ellis PD, McBride S, Kirschenlohr HL, Healey CS, et al. (2003) A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 63: 2610-2615. PubMed: 12750287.
10. Yokota M, Ichihara S, Lin TL, Nakashima N, Yamada Y, (2000) Association of a T29--C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 101: 2783-2787. doi:10.1161/01.CIR.101.24.2783. PubMed: 10859282.
11. Mantel N, Haenszel W, (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748. PubMed: 13655060.
12. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188. doi:10.1016/0197-2456(86)90046-2. PubMed: 3802833.
13. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634. doi:10.1136/bmj.315.7109.629. PubMed: 9310563.
14. Duval S, Tweedie R, (2000) Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56: 455-463. doi:10.1111/j.0006-341X.2000.00455.x. PubMed: 10877304.
15. Peters CA, Stock RG, Cesaretti JA, Atencio DP, Peters S, et al. (2008) TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 70: 752-759. doi:10.1016/j.ijrobp.2007.05.023. PubMed: 17689884.
16. Thurner EM, Krenn-Pilko S, Renner W, Gerger A, Kapp KS, et al. (2012) Genetic variants in the TGF-beta1 gene and the risk of late toxicity after radiotherapy in prostate cancer patients.
17. Barnett GC, Coles CE, Elliott RM, Baynes C, Luccarini C, et al. (2012) Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. Lancet Oncol 13: 65-77. doi:10.1016/S1470-2045(11)70302-3. PubMed: 22169268.
18. Lyons AJ, Shaw R, West C, (2011) Osteoradionecrosis and trismus following radiotherapy is genotype dependent.
19. Zhang G, Fan M, Jiang G, Fu X, Chen J, et al. (2010) Association between polymorphisms in DNA repair and inflammatory response genes and ctcae 3.0 grade 2 or worse esophagitis induced by neoadjuvant platinum-based chemotherapy and thoracic radiotherapy.
20. Yuan ST, Ellingrod VL, Schipper M, Stringer KA, Cai X, et al. (2013) Genetic variations in TGFbeta1, tPA, and ACE and radiation-induced thoracic toxicities in patients with non-small-cell lung cancer. J Thorac Oncol 8: 208-213. doi:10.1097/JTO.0b013e318274592e. PubMed: 23334061.
21. Fachal L, Gómez-Caamaño A, Sánchez-García M, Carballo A, Peleteiro P, et al. (2012) TGFbeta1 SNPs and radio-induced toxicity in prostate cancer patients. Radiother Oncol 103: 206-209. doi:10.1016/S0167-8140(12)70851-4. PubMed: 22385796.
22. Terrazzino S, La Mattina P, Gambaro G, Masini L, Franco P, et al. (2012) Common variants of GSTP1, GSTA1, and TGFbeta1 are associated with the risk of radiation-induced fibrosis in breast cancer patients. Int J Radiat Oncol Biol Phys 83: 504-511. PubMed: 22079734.
23. Alsbeih G, Al-Harbi N, Al-Hadyan K, El-Sebaie M, Al-Rajhi N, (2010) Association between normal tissue complications after radiotherapy and polymorphic variations in TGFB1 and XRCC1 genes. Radiat Res 173: 505-511. doi:10.1667/RR1769.1. PubMed: 20334523.
24. Damaraju S, Murray D, Dufour J, Carandang D, Myrehaug S, et al. (2006) Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. Clin Cancer Res 12: 2545-2554. doi:10.1158/1078-0432.CCR-05-2703. PubMed: 16638864.
25. Barnett GC, Coles CE, Burnet NG, Pharoah PD, Wilkinson J, et al. (2010) No association between SNPs regulating TGF-beta1 secretion and late radiotherapy toxicity to the breast: results from the RAPPER study. Radiother Oncol 97: 9-14. doi:10.1016/j.radonc.2009.12.006. PubMed: 20096948.
26. Martin S, Sydenham M, Haviland J, A'Hern R, Owen R, et al. (2010) Test of association between variant tgbeta1 alleles and late adverse effects of breast radiotherapy. Radiother Oncol 97: 15-18. doi:10.1016/j.radonc.2010.03.019. PubMed: 20435363.
27. Zschenker O, Raabe A, Boeckelmann IK, Borstelmann S, Szymczak S, et al. (2010) Association of single nucleotide polymorphisms in ATM, GSTP1, SOD2, TGFB1, XPD and XRCC1 with clinical and cellular radiosensitivity. Radiother Oncol 97: 26-32. doi:10.1016/j.radonc.2010.01.016. PubMed: 20170971.
28. Quarmby S, Fakhoury H, Levine E, Barber J, Wylie J, et al. (2003) Association of transforming growth factor beta-1 single nucleotide polymorphisms with radiation-induced damage to normal tissues in breast cancer patients. Int J Radiat Biol 79: 137-143. doi:10.1080/0955300021000045673. PubMed: 12569017.
29. De Ruyck K, Van Eijkeren M, Claes K, Bacher K, Vral A, et al. (2006) TGFbeta1 polymorphisms and late clinical radiosensitivity in patients treated for gynecologic tumors. Int J Radiat Oncol Biol Phys 65: 1240-1248. doi:10.1016/j.ijrobp.2006.03.047. PubMed: 16798416.
30. Andreassen CN, Alsner J, Overgaard M, Overgaard J, (2003) Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. Radiother Oncol 69: 127-135. doi:10.1016/j.radonc.2003.09.010. PubMed: 14643949.
31. Andreassen CN, Alsner J, Overgaard J, Herskind C, Haviland J, et al. (2005) TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. Radiother Oncol 75: 18-21. doi:10.1016/j.radonc.2004.12.012. PubMed: 15878096.
32. Giotopoulos G, Symonds RP, Foweraker K, Griffin M, Peat I, et al. (2007) The late radiotherapy normal tissue injury phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependent causes. Br J Cancer 96: 1001-1007. doi:10.1038/sj.bjc.6603637. PubMed: 17325707.
33. Andreassen CN, Alsner J, Overgaard M, Sørensen FB, Overgaard J, (2006) Risk of radiation-induced subcutaneous fibrosis in relation to single nucleotide polymorphisms in TGFB1, SOD2, XRCC1, XRCC3, APEX and ATM--a study based on DNA from formalin fixed paraffin embedded tissue samples. Int J Radiat Biol 82: 577-586. doi:10.1080/09553000600876637. PubMed: 16966185.
34. Suga T, Iwakawa M, Tsuji H, Ishikawa H, Oda E, et al. (2008) Influence of multiple genetic polymorphisms on genitourinary morbidity after carbon ion radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 72: 808-813. doi:10.1016/j.ijrobp.2008.01.029. PubMed: 18374504.
35. Azria D, Ozsahin M, Kramar A, Peters S, Atencio DP, et al. (2008) Single nucleotide polymorphisms, apoptosis, and the development of severe late adverse effects after radiotherapy. Clin Cancer Res 14: 6284-6288. doi:10.1158/1078-0432.CCR-08-0700. PubMed: 18829510.
36. Finkelstein JN, Johnston CJ, Baggs R, Rubin P, (1994) Early alterations in extracellular matrix and transforming growth factor beta gene expression in mouse lung indicative of late radiation fibrosis. Int J Radiat Oncol Biol Phys 28: 621-631. doi:10.1016/0360-3016(94)90187-2. PubMed: 8113105.
37. Anscher MS, Crocker IR, Jirtle RL, (1990) Transforming growth factor-beta 1 expression in irradiated liver. Radiat Res 122: 77-85. doi:10.2307/3577586. PubMed: 2181527.
38. Ehrhart EJ, Segarini P, Tsang ML, Carroll AG, Barcellos-Hoff MH, (1997) Latent transforming growth factor beta1 activation in situ: quantitative and functional evidence after low-dose gamma-irradiation. FASEB J 11: 991-1002. PubMed: 9337152.
39. Ewan KB, Henshall-Powell RL, Ravani SA, Pajares MJ, Arteaga C, et al. (2002) Transforming growth factor-beta1 mediates cellular response to DNA damage in situ. Cancer Res 62: 5627-5631. PubMed: 12384514.
40. Evans ES, Kocak Z, Zhou SM, Kahn DA, Huang H, et al. (2006) Does transforming growth factor-beta1 predict for radiation-induced pneumonitis in patients treated for lung cancer? Cytokine 35: 186-192. doi:10.1016/j.cyto.2006.07.021. PubMed: 16979900.
41. El-Gamel A, Awad MR, Hasleton PS, Yonan NA, Hutchinson JA, et al. (1999) Transforming growth factor-beta (TGF-beta1) genotype and lung allograft fibrosis. J Heart Lung Transplant 18: 517-523. doi:10.1016/S1053-2498(98)00024-2. PubMed: 10395349.